Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback